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S U M M A R Y
Background: The epidemiology of invasive pneumococcal disease (IPD) in children aged5 years in Saudi
Arabia has not been described. We conducted a retrospective surveillance study to describe the
epidemiology of IPD in the population of children aged 5 years served by the National Guard Health
Affairs hospitals in central and western regions of Saudi Arabia.
Methods: We reviewed the medical records of children 5 years old admitted to the King Abdulaziz
Medical City hospitals in Riyadh and Jeddah with pneumococcal infections for the period January 1999
through December 2003. Only microbiologically conﬁrmed IPD cases (meningitis or bacteremia) were
included in the analysis.
Results: A total of 82 IPD cases, 19 (23.2%) meningitis and 63 (76.8%) bacteremia, were diagnosed during
the ﬁve-year period. Of these, 12.2% (10/82) died, with a case-fatality slightly but insigniﬁcantly higher in
cases of meningitis (15.8%) than bacteremia (11.1%). The average annual IPD incidence was 17.4 per 100
000 (4.0 for meningitis and 13.4 for bacteremia). The incidence was roughly similar in males and females
(18.3 and 16.6, respectively; p = 0.663) and was almost 4-fold higher in the ﬁrst year of life compared to
the next four years (40.6 and 11.5, respectively; p < 0.001). The average annual IPDmortality was 2.1 per
100 000 and was higher in the ﬁrst year of life compared to the next four years (5.2 and 1.3 , respectively;
p = 0.043).
Conclusions: In the pre-vaccination era (1999–2003) in Saudi Arabia, IPD incidence was comparable to
the pre-vaccination incidence rates from many industrialized countries, with children aged 1 year
suffering the highest IPD risk among those aged 5 years.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Streptococcus pneumoniae is a leading cause of morbidity and
mortality among children worldwide. Non-invasive pneumococcal
diseases include bacterial pneumonia, acute otitis media, and
sinusitis, while invasive pneumococcal diseases (IPD) include
bacteremia, sepsis, and meningitis.1 There is a worldwide
increasing resistance to b-lactam therapy previously effective
against IPD. It has been estimated that 15% to 30% of S. pneumoniae
worldwide are currently multidrug-resistant.2 It remains unclear
whether this antimicrobial resistance has a signiﬁcant effect on IPD
morbidity and mortality, especially in light of the availability of an* Corresponding author. Tel.: +966 1 2520088x43720; fax: +966 1 2520437.
E-mail addresses: zmemish@yahoo.com, memish@ngha.med.sa (Z.A. Memish).
1201-9712/$36.00 – see front matter  2010 International Society for Infectious Disea
doi:10.1016/j.ijid.2010.02.2242effective pneumococcal vaccine.3,4 In Saudi Arabia, the 7-valent
pneumococcal conjugate vaccine (PCV7) was introduced within
the National Guard community only for high-risk children (aged
<2 years) in 2006 and to all children in their ﬁrst year of life in
January 2008; it was introduced nationally by the Ministry of
Health in January 2009.5,6
The World Health Organization (WHO) estimated that about
one million children aged <5 years die of pneumococcal disease
every year, most of whom live in developing countries.7 The true
worldwide burden of pneumococcal infections in children <5
years old is actually under-documented, particularly in developing
countries.7,8 Moreover, there is a wide international variability in
IPD incidence even within industrialized countries, mainly due to
differences in surveillance systems and the availability of
diagnostic techniques.9 Not surprisingly, there is a lack of
epidemiological data on IPD, particularly incidence and mortality,ses. Published by Elsevier Ltd. All rights reserved.
Table 1
Demographic characteristics of children aged 5 years with IPD at KAMC hospitals
in Riyadh and Jeddah, Saudi Arabia, 1999–2003
Meningitis Bacteremia Total p-Valuea
Total 19 (23.2%) 63 (76.8%) 82 (100%) NA
Gender
Male 10 (52.6%) 34 (54.0%) 44 (53.7%) 0.918
Female 9 (47.4%) 29 (46.0%) 38 (46.3%)
Age at diagnosis (years)
1 12 (63.2%) 27 (42.9%) 39 (47.6%)
>1–2 4 (21.1%) 18 (28.6%) 22 (26.8%)
>2–3 1 (5.3%) 3 (4.8%) 4 (4.9%) 0.567
>3–4 1 (5.3%) 10 (15.9%) 11 (13.4%)
>4–5 1 (5.3%) 5 (7.9%) 6 (7.3%)
Year of diagnosis
1999 2 (10.5%) 9 (14.3%) 11 (13.4%)
2000 3 (15.8%) 11 (17.5%) 14 (17.1%)
2001 4 (21.1%) 20 (31.7%) 24 (29.3%) 0.730
2002 4 (21.1%) 7 (11.1%) 11 (13.4%)
2003 6 (31.6%) 16 (25.4%) 22 (26.8%)
IPD, invasive pneumococcal diseases; KAMC, King Abdulaziz Medical City.
a The Chi-square test was used to detect signiﬁcant differences.
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Saudi Arabia.10 IPD incidence and mortality data for Saudi Arabia
are critically needed to evaluate the potential beneﬁts of the
recently introduced PCV7 vaccine for infants, as well as any
potential problems as a result of the recently reported increase in
antimicrobial resistance in S. pneumoniae.11–13 We conducted a
retrospective hospital surveillance study for the period 1999 to
2003 to calculate the pre-vaccination IPD morbidity and mortality
among the population of children aged 5 years served by the
National Guard Health Affairs (NGHA) hospitals in central and
western regions of Saudi Arabia.
2. Methods
2.1. Study population
The current study was conducted at two out of the four NGHA
hospitals: the King Abdulaziz Medical City (KAMC) hospitals in
Riyadh and Jeddah, Saudi Arabia. In 2003, the two hospitals
(about 1500 beds in total) and their primary care centers
provided medical care for almost 750 000 National Guard
employees and their dependents (spouses, children, and
parents) in the central and western regions of Saudi Arabia.
The NGHA served a population (97% Saudi) representing
approximately 3.4% of the total population of Saudi Arabia
(22.0 million in 2000 and 23.7 million in 2006). Children 5
years of age represented an average 13.3% of the total NGHA
served population. The care provided by the NGHA hospitals and
primary care centers ranged from primary and preventive care
to tertiary care.
2.2. Study design
The current study design was a retrospective hospital surveil-
lance study to examine microbiologically conﬁrmed IPD cases.
Records reviewedwere all medical records of children5 years old
admitted with pneumococcal infections to pediatric units of KAMC
in Riyadh and Jeddah, from January 1999 through December 2003.
Demographic information, diagnostic tests, risk factors and co-
morbidities, antibiotic treatment and resistance, and outcome data
were extracted using a structured data collection form. Informa-
tion on pre-diagnosis antibiotic use was not collected. Resistance
rates against S. pneumoniae for b-lactams, macrolides, and other
medications (tetracycline, co-trimoxazole, sulfamethoxazole, and
clindamycin) were calculated as the sum of intermediately
susceptible and resistant S. pneumoniae relative to the total
number of S. pneumoniae tested.
2.3. Case deﬁnition
IPD was deﬁned as a pneumococcal infection that results in
dissemination of S. pneumoniae to the bloodstream (causing
bacteremia) and the central nervous system (causing meningitis).1
The episode severity was clinically assessed by the treating
physician based on clinical signs and symptoms, need for intensive
care, associated risk factors, and co-morbidities.1 Reviewed cases
of pneumococcal infection were identiﬁed based on the discharge
diagnosis and microbiology laboratory results. Possible IPD cases
were conﬁrmed after isolation of S. pneumoniae from the blood or
cerebrospinal ﬂuid (CSF) cultures. Only microbiologically con-
ﬁrmed cases were included in the analysis and only one culture per
disease episode was analyzed. S. pneumoniae-positive cultures
identiﬁed at least 30 days apart were considered as two separate
cases (applied only in one child). For patients with meningitis
where both CSF and blood samples were taken for culture, the
results of the CSF sample were used in the analysis.2.4. Statistical methods
Incidence rates for IPD were calculated by gender, age-group,
and year of diagnosis by dividing the number of conﬁrmed cases of
IPD by the corresponding estimated NGHA served child population
(5 years) multiplied by 100 000. Mortality rates were calculated
in a similar way, but only deaths associated with IPD were used.
Case-fatality was calculated by dividing the deaths associatedwith
IPD episodes by all IPD cases diagnosed. The percentages of IPD
cases diagnosed each month were plotted to detect seasonal
variations in IPD incidence. Signiﬁcant differences between
meningitis and bacteremia were tested using the Chi-square or
Fisher’s exact tests (as appropriate) for categorical variables and
the Mann-Whitney U-test for continuous variables. All p-values
were two-tailed. A p-value of <0.05 was considered as signiﬁcant.
SPSS software (release 15.0; SPSS Inc., Chicago, IL, USA) was used
for all statistical analyses.
3. Results
A total of 82 IPD cases, 19 (23.2%) meningitis and 63 (76.8%)
bacteremia, were diagnosed over the ﬁve-year period (1999–
2003). Demographic characteristics of children aged5 years with
IPD are shown in Table 1. Of the patients, 53.7% were male and
46.3% female. About half of the patients (47.6%) were 1 year of
age and approximately 75%were2 years of age. More than 80% of
patients were admitted to KAMC-Riyadh. The number of children
aged 5 years served by KAMC in Riyadh and Jeddah ranged from
88.6 thousand in 1999 to 99.4 thousand in 2003, with an annual
average of 93.9 thousand children.
Details of IPD risk factors and co-morbidities are listed in
Table 2. Approximately 30% of the IPD cases had a severe episode.
There was a tendency towards a higher percentage of severe cases
in meningitis than bacteremia (42.1% vs. 23.8%, non-signiﬁcant).
The IPD episode ended in recovery without residual chronicity or
disability in 78.0% of cases. Approximately 16% of IPD cases were
not breastfed. Lack of breastfeeding was signiﬁcantly associated
with meningitis rather than bacteremia (p = 0.001). About 12% of
all IPD cases had recently taken antibiotics (within 3 months).
About 6% of all IPD cases had complicated or bacteremic
pneumonia. Approximately 5–10% of those who had bacteremia
(and none of those who had meninigitis) were premature (<37
weeks), attended day care, or had neoplastic diseases, chronic liver
disease, or nephrotic syndrome.
Table 2
Clinical and prognostic characteristics of IPD in children aged 5 years at KAMC
hospitals in Riyadh and Jeddah, Saudi Arabia, 1999–2003
Meningitis Bacteremia Total p-Value
Episode severity
Mild 6 (31.6%) 32 (50.8%) 38 (46.3%)
Moderate 5 (26.3%) 16 (25.4%) 21 (25.6%) 0.233
Severe 8 (42.1%) 15 (23.8%) 23 (28.0%)
Outcome
Recovery 13 (68.4%) 51 (81.0%) 64 (78.0%)
Death 3 (15.8%) 7 (11.1%) 10 (12.2%) 0.477
Residual effect 3 (15.8%) 5 (7.9%) 8 (9.8%)
Risk factors or co-morbidities
Lack of breastfeeding 8 (42.1%) 5 (7.9%) 13 (15.9%) 0.001a
Recent antibiotic intake 1 (5.3%) 9 (14.3%) 10 (12.2%) 0.440a
Day care attendance 0 (0%) 6 (9.5%) 6 (7.3%) 0.328a
Neoplastic diseases 0 (0%) 6 (9.5%) 6 (7.3%) 0.328a
Prematurity (<37 weeks) 0 (0%) 5 (7.9%) 5 (6.1%) 0.585a
Chronic liver disease 0 (0%) 4 (6.3%) 4 (4.9%) 0.569a
Nephrotic syndrome 0 (0%) 3 (4.8%) 3 (3.7%) >0.90a
Immunodeﬁciencies 0 (0%) 1 (1.6%) 1 (1.2%) >0.90a
History of otitis media 0 (0%) 1 (1.6%) 1 (1.2%) >0.90a
Cerebral ﬂuid leaks 1 (5.3%) 0 (0%) 1 (1.2%) 0.232a
Sickle cell anemia 1 (5.3%) 0 (0%) 1 (1.2%) 0.232a
IPD, invasive pneumococcal diseases; KAMC, King Abdulaziz Medical City.
a Fisher’s exact test rather than the Chi-square test was used to detect signiﬁcant
differences.
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cases required an average 3-fold longer duration of hospital
admission than bacteremia cases (16 vs. 5 days, p < 0.001).
Moreover, meningitis cases required ICU admission more fre-
quently than bacteremia cases (52.6% vs. 19.0%, p = 0.004), but
stayed the same duration on ICU admission (7 days). Meningitis
cases were usually treated with two or more antibiotics (84.2%),
whereas bacteremia cases were frequently treated with oneTable 3
Management of IPD in children aged 5 years at KAMC hospitals in Riyadh and Jeddah
Meningitis
Hospital LOS (median, days) 16.0
ICU admission 10 (52.6%)
ICU LOS (median, days) 7.0
Ventilator use 4 (21.1%)
Number of antibiotics used
0 0 (0%)
1 3 (15.8%)
2 16 (84.2%)
Duration of antibiotic use (median, days) 19.0
Antibiotics used
Cefuroxime 1 (5.3%)
Ceftriaxone 14 (73.7%)
Vancomycin 15 (78.9%)
Cefotaxime 5 (26.3%)
Ceftazidime 2 (10.5%)
Amoxicillin–clavulanate 0 (0%)
Ampicillin 0 (0%)
Amikacin 0 (0%)
Antibiotic resistance
Overall 8 (42.1%)
b-Lactam resistance 6 (31.6%)
Macrolide resistance 3 (15.8%)
Other resistance 5 (26.3%)
Antibiotic resistance to
1–2 classes 7 (87.5%)
3 classes 1 (12.5%)
IPD, invasive pneumococcal diseases; KAMC, King Abdulaziz Medical City; LOS, length
a Mann-Whitney U-test was used to detect signiﬁcant differences.
b Fisher’s exact test rather than the Chi-square test was used to detect signiﬁcant dantibiotic (61.9%). The duration of antibiotic treatment was
signiﬁcantly longer in meningitis than bacteremia (p = 0.001).
The antibiotics most frequently used for the treatment of
meningitis were vancomycin (78.9%) and ceftriaxone (73.7%),
while the antibiotics most frequently used for the treatment of
bacteremia were cefuroxime (39.7%) and ceftriaxone (30.2%).
Approximately one third of IPD cases (34.1%) had some type of
antimicrobial resistance. b-Lactam resistance and macrolide
resistance were the most frequently encountered (25.6% and
7.3%, respectively). Only 7.1% of all antimicrobial resistance was
multi-drug resistance (resistant to three or more antimicrobial
classes).
The average annual IPD incidence was 17.4 per 100 000
(Table 4). Bacteremia incidence was >3-fold higher than meningi-
tis incidence (13.4 vs. 4.0 per 100 000, respectively). The IPD
incidence was roughly similar in males and females (18.3 and 16.6,
respectively; p = 0.663) and was almost 4-fold higher in the ﬁrst
year of life compared to the next four years (40.6 and 11.5,
respectively; p < 0.001). The IPD incidence declined sharply after
the second year of life (Figure 1). The IPD incidence did not show a
signiﬁcant upward or downward trend over the years of the study.
Diagnosed meningitis cases showed clear seasonal variation
(Figure 2), with the majority being diagnosed in the ﬁrst and last
quarters of the year. A similar but less clear seasonal variation
pattern was observed for bacteremia cases.
The average annual IPD mortality was 2.1 per 100 000. The
mortality was not signiﬁcantly different between males and
females (1.7 and 2.6, respectively; p = 0.693), but was higher in the
ﬁrst year of life compared to the next four years (5.2 and 1.3,
respectively; p = 0.043). In fact, all meningitismortality occurred in
the ﬁrst year of life. The IPD case-fatality was slightly but
insigniﬁcantly higher in meningitis cases (15.8%) compared to
bacteremia cases (11.1%) (p = 0.477). Death was correlated with
the episode severity, but was not associated with age, gender, or, Saudi Arabia, 1999–2003
Bacteremia Total p-Value
5.0 7.0 <0.001a
12 (19.0%) 22 (26.8%) 0.004
7.0 7.0 0.868a
7 (11.1%) 11 (13.4%) 0.265
3 (4.8%) 3 (3.7%)
39 (61.9%) 42 (51.2%) <0.001
21 (33.3%) 37 (45.1%)
11.0 12.0 0.001a
25 (39.7%) 26 (31.7%) 0.005
19 (30.2%) 33 (40.2%) 0.001
7 (11.1%) 22 (26.8%) <0.001
9 (14.3%) 14 (17.1%) 0.296
6 (9.5%) 8 (9.8%) >0.90b
8 (12.7%) 8 (9.8%) 0.188b
6 (9.5%) 6 (7.3%) 0.328b
5 (7.9%) 5 (6.1%) 0.585b
20 (31.7%) 28 (34.1%) 0.404
15 (23.8%) 21 (25.6%) 0.553b
3 (4.8%) 6 (7.3%) 0.134b
13 (20.6%) 18 (22.0%) 0.752b
19 (95%) 26 (92.9%) 0.486b
1 (5%) 2 (7.1%)
of stay; ICU, intensive care unit.
ifferences.
Table 4
Incidence, mortality, and case-fatality of IPD in children aged 5 years at KAMC
hospitals in Riyadh and Jeddah, Saudi Arabia, 1999–2003
Meningitis Bacteremia Total
Incidence per 100 000
Overall 4.0 13.4 17.4
Gender:
Male 4.2 14.1 18.3
Female 3.9 12.7 16.6
p=0.904 p=0.666 p=0.663
Age at diagnosis
1 year 12.5 28.1 40.6
>1–5 years 1.9 9.6 11.5
p < 0.001 p<0.001 p<0.001
Year of diagnosisa
1999 2.3 10.2 12.4
2000 3.3 12.1 15.4
2001 4.3 21.3 25.6
2002 4.1 7.2 11.4
2003 6.0 16.1 22.1
p=0.230 p=0.600 p=0.282
Mortality per 100 000b
Overall 0.6 1.5 2.1
Gender:
Male 0.8 0.8 1.7
Female 0.4 2.2 2.6
p=0.653 p=0.413 p=0.693
Age at diagnosis
1 year 3.1 2.1 5.2
>1–5 years 0.0 1.3 1.3
p=0.017 p=0.870 p=0.043
Case-fatality (%)b
Overall 15.8% 11.1% 12.2%
Gender
Male 20.0% 5.9% 9.1%
Female 11.1% 17.2% 15.8%
p=0.218 p > 0.900 p=0.502
Age at diagnosis
1 year 25.0% 7.4% 12.8%
>1–5 years 0.0% 13.9% 11.6%
p=0.159 p=0.572 p>0.900
IPD, invasive pneumococcal diseases; KAMC, King Abdulaziz Medical City
a Chi-square for trend was used to detect signiﬁcant trends.
b Fisher’s exact test rather than the Chi-square test was used to detect signiﬁcant
differences.
Figure 2. Seasonality of IPD diagnosis among children aged 5 years at KAMC
hospitals in Riyadh and Jeddah, Saudi Arabia, 1999–2003.
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breastfeeding. Compared to the rest of IPD cases, fatal cases were
more likely to be admitted to the ICU, use the ventilator, and have a
longer duration of antibiotics.Figure 1. Incidence of IPD per 100 000 children aged 5 years by age-group at
KAMC hospitals in Riyadh and Jeddah, Saudi Arabia, 1999–2003.4. Discussion
The current report describes, for the ﬁrst time, the incidence
and mortality indicators of IPD over a ﬁve-year period (1999–
2003), in a large population of young children (5 years) served by
the NGHA hospitals in the central and western regions of Saudi
Arabia. The reported IPD incidence and mortality data, collected
before the introduction of the PCV7 vaccine for either high-risk
children or all infants, are important in evaluating the potential
beneﬁts of the recently introduced vaccine. Similar to classic IPD
epidemiology worldwide, meningitis in Saudi Arabia had a lower
incidence and prevalence but higher mortality compared to
bacteremia; children 1 year of age in Saudi Arabia suffered the
highest IPD risk among those aged 5 years and more cases were
diagnosed in the winter months than the rest of the year.9,10,14,15
The average annual IPD incidence was 17.4 per 100 000 with
bacteremia representing approximately three-fourths (13.4 per
100 000) and meningitis one-fourth (4.0 per 100 000) of the
incidence burden. National data describing IPD incidence and
mortality in children <5 years of age are generally lacking. We are
aware of only one study from Saudi Arabia that has estimated the
incidence of pneumococcal meningitis in children <5 years old.
The estimates from that study, designed to examine the burden of
bacterial meningitis, were comparable to the currently reported
rates, with ﬁndings of 3.4 to 9.0 (average 6.7) per 100 000 in
different regions of Saudi Arabia between 1999 and 2001.16
Regional data were not any better. A recently published review of
IPD epidemiology in the Arabian Peninsula and Egypt10 failed to
identify a single study outside Saudi Arabia that had estimated IPD
incidence in children aged <5 years.
Internationally, there is huge variability in IPD incidence, not only
between developing and developed countries, but also within
industrialized countries.9,17 For example, in children aged <5 years,
IPD incidence in Europe (per 100 000) has been shown to range
between7.6inSwitzerlandand56.2 inSpain.9,18Suchvariabilitymay
be caused bydifferences in surveillance systems, reportingmethods,
reporting phase (pre- vs. post-large-scale vaccination), hospitaliza-
tion policies, availability of diagnostic techniques, and the use of
empirical antibiotic therapies.9,17,19 The current reported IPD
incidence in Saudi Arabia is generally comparable to pre-vaccination
incidence reports from Western Europe20–22 and post-vaccination
reports from the USA and Australia.3,23 Our rates, however, are
considerably lower than pre-vaccination incidence reports from the
USAandAustralia.24–26FewstudieshavereportedIPDincidencerates
from developing countries and all have been considerably higher
(range 111 to 436 per 100 000 children aged <5 years) than the
current reported rates from Saudi Arabia.14,27,28
Local and regionalmortalitydata are lacking. Case-fatalitydata in
the current report (12%) are in accordance with previous data from
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but slightly higher than data from developed countries in the pre-
vaccination era.24,26,31 Some countries have experienced an
approximate 75% decrease in case-fatality following the introduc-
tion of PCV7 into the infant immunization schedule.32 Given the
incidence and mortality rates calculated in this report and Saudi
national statistics (24.2 million population in 2007), we estimate
that at least 490 IPD cases occur in Saudi Arabia every year among
children aged <5 years and that the recently introduced vaccine
could save about 45 out of the 60 associated deaths.
Only 7% of all antimicrobial resistance detected in IPD cases in
the current study was multi-drug resistance (resistance to three or
more antimicrobial classes). This is probably much less than that
reported in many parts of the world.2 Moreover, the currently
reportedb-lactam andmacrolide resistance rates are probably less
than previously reported rates. For exampleb-lactam resistance in
the current study was estimated at 25.6% compared to rates of
between 40% and 60% in previous reports.11–13,33 Similarly,
macrolide resistance in the current study was estimated at 7.3%
compared to rates of between 8% and 26% in previous reports.11–
13,34 These differences may partly be explained by the duration
covered by different studies and by the antimicrobial policies at the
different hospitals. Although b-lactam resistance and macrolide
resistance were relatively low, none of these antibiotics were used
in managing IPD cases; instead second- and third-generation
cephalosporins and vancomycin were mainly used.
The current study hadmany strengths in studying IPD incidence
and mortality, with potentially stable ﬁndings: the relatively large
and clearly deﬁned study population, the long study duration, and
the consistency of case deﬁnition and diagnostic techniques in all
NGHA hospitals. Nevertheless, we acknowledge some limitations:
the retrospective design and the possibility of underestimating the
true IPD burden. However, underestimation is largely inevitable in
all hospital surveillance studies because of missed cases. Although
it is difﬁcult to quantify, rates of underestimation probably did not
have a major impact on the current ﬁndings because of the
availability of free medical care (including microbiological
conﬁrmation and medications) to the study population. Only
12% of all IPD cases had a history of recent (within 3 months)
antibiotic intake including empirical pre-treatment. Our ﬁndings
may be generalized to the whole population of Saudi Arabia,
acknowledging minor demographic differences.
In conclusion, we have reported IPD incidence and mortality
indicators in a large population of children aged 5 years in Saudi
Arabia for the ﬁrst time. IPD incidence and case-fatality were
largely comparable to those reported in many industrialized
countries. Meningitis had a lower incidence and prevalence but
higher mortality compared to bacteremia. Children aged 1 year
suffered the highest IPD risk among those aged 5 years. These
results are critical in evaluating the potential impact and cost-
effectiveness of the recently introduced PCV7 vaccine to the
regular infant immunization schedule.
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